The aims of Susan G. Komen for the Cure

Exchanging scientific information

Bisphosphonates for breast cancer patients

Typical course for receptor positive early breast cancer

The role of funding and policies on innovation in cancer drug development

UK cancer reform strategy: impact so far and next steps

Oral bisphosphonate and breast cancer: prospective results from the Women's Health Initiative (WHI)

Use of bisphosphonates and risk of postmenopausal breast cancer

Denosumab versus zoledronic acid for skeletal-related events in breast cancer patients with bone metastases

Short term biological effects of the combination of letrozole and zoledronic acid on invasive breast cancer

Targeting intrinsically-resistant breast cancer stem cells with gamma-secretase inhibitors

Fulvestrant 250 mg vs 500 mg in postmenopausal women with oestrogen receptor-positive advanced breast cancer